BREAKING NEWS

US Food and Drug Administration approves Teva leukemia drug

The US Food and Drug Administration on Friday said it has approved a new leukemia treatment from Israel-headquartered Teva Pharmaceutical Industries Ltd to be sold under the brand name Synribo.
The drug, also known as omacetaxine mepesuccinate, is approved to treat a type of the blood and bone marrow cancer called chronic myelogenous leukemia, or CML, in patients whose cancer has progressed after treatment with at least two drugs from a class called tyrosine kinase inhibitors."Today's approval provides a new treatment option for patients who are resistant to or cannot tolerate other FDA-approved drugs for chronic or accelerated phases of CML," Richard Pazdur, director of the Office of Hematology and Oncology Products in FDA's Center for Drug Evaluation and Research, said in a statement.
Subscribe for our daily newsletter
Subscribe for our daily newsletter

By subscribing I accept the terms of use

Read all Tweets >